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Most human papillomavirus (HPV) positive head and neck cancers arise in
the tonsil crypts; deep invaginations at the tonsil surface that are lined with
reticulated epithelium infiltrated by immune cells. As in cervical HPV infec-
tions, HPV16 is the most prevalent high-risk type in the oropharyngeal
cancers, and a genital-oral route of infection is most likely. However, the
natural history of HPV-driven oropharyngeal pathogenesis is an enigma,
although there is evidence that it is different to that of cervical disease. It
is not known if the virus establishes a productive or abortive infection in ker-
atinocytes of the tonsil crypt, or if viral infections progress to cancer via a
neoplastic phase, as in cervical HPV infection. The HPV DNA is more fre-
quently found unintegrated in the cancers of the oropharynx compared to
those that arise in the cervix, and may include novel HPV-human DNA
hybrids episomes. Here, we review current understanding of HPV biology
in the oropharynx and discuss the cell-based systems being used to model
the HPV life cycle in tonsil keratinocytes and how they can be used to
inform on HPV-driven neoplastic progression in the oropharynx.
This article is part of the theme issue ‘Silent cancer agents: multi-
disciplinary modelling of human DNA oncoviruses’.1. Human papillomavirus-driven cancer in the oropharynx
In the United Kingdom (UK), the age-standardized incidence rate of oropharyn-
geal squamous cell carcinoma (OPSCC) has tripled in men and doubled in
women between 1995–2011 and similar trends have been reported in the
United States (US), and in other parts of the world [1,2]. A human papilloma-
virus (HPV) infection is a significant contributing factor to the rising trend and
is notably associated with cancers of lymphoepithelial sites within the orophar-
ynx; specifically within the tonsil and the base of tongue [1,3–6]. Intriguingly,
some studies have shown a levelling out of HPV prevalence in tumours post-
2002, suggesting factors other than HPV may be driving the increase in
OPSCC in later years [1,7]. The worldwide burden of OPSCC attributable to
HPV is estimated to be a third of all OPSCC cases (29 000 cases per year).
There is a greater incidence of HPV-positive OPSCC in the developed rather
than less developed countries, with North America and Europe with the highest
number of cases [8]. These virus-associated cancers were found to be more
common in young (less than 60 years), male patients, although more recent
studies identified expansion of the elderly population (greater than 70 years)
with HPV-positive disease [9]. Sexual behaviour measured as lifetime number
of oral sexual partners is a very strong risk factor for HPV-OPSCC, indicating
that an genital-oral route for oral HPV infection is most likely [2,10,11]. Smoking
may also have a biological effect upon the natural history of oral HPV infection
and OPSCC development since this behaviour has been linked to an increase in
acquisition and/or persistence of oral HPV infection [12–14].
There ismuch interest in patients withHPV-OPSCC because they have overall
increased survival compared to thosewith HPV-negative disease, and thus it has
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2been proposed that this group of younger patients could
benefit from deintensification of therapy to reduce the longer
term toxicities in anticipation of long-term survival [15,16].
However, two recent clinical trials have demonstrated that
treatment deintensification in low-risk HPV-OPSCC from
cisplatin-based chemoradiotherapy to cetuximab bioradiother-
apy did not result in reduced toxicity and the deintensified
patients had reduced overall survival [17,18]. Also, despite
the better survival of patients with HPV-positive tumours
there is a significant minority of patients that respond poorly
to treatment and have a poor prognosis. While reduced treat-
ment response in this group of patients has been correlated
with heavy cigarette smoke exposure [15,19], the oropharynx
sub-site origin of the tumour determines clinical outcome [3].
Thus, tumours that have arisen from the lymphoepithelial
sites of the tonsil and base of tongue show beneficial survival
compared to HPV-negative tumours at these sites, but patients
with HPV-positive tumours originating from oropharyn-
geal sites outside of the lymphoepithelial tissues have no
advantage in outcome compared to virus-negative cancers
[3]. Nevertheless, there is currently no widely accepted
strategy to identify patients that will respond better to treat-
ment. However, HPV-OPSCC tumours with low numbers of
tumour-infiltrating lymphocytes (TIL) have a poorer progno-
sis, and this could be used to predict those patients that will
respond poorly to treatment [20].
The high-risk (HR) HPV types found in cervical cancers
are also present in OPSCC and HPV16 is the most prevalent
HR type in both types of tumour [21]. However, a far greater
proportion (over 80%) of OPSCC are HPV16-positive com-
pared to cervical tumours in which approximately 60% are
HPV16-positive [22]. In addition, the frequency of HPV18 is
far less in OPSCC (less than 2%) than in cervical disease
(10%); and in fact, HPV33 is the second most prevalent HR
type in OPSCC (3.3%) [21,23]. The reasons for HPV16 domi-
nance over the other HR viruses in OPSCC is not clear, but
could reflect the nature of the target cell of infection within
the tonsil, which may be different between HPV16 and the
other HPV types, differences between the infectious cycles
or the interaction of these viruses with the host immune
response. With regard to the latter possibility, primary
foreskin keratinocytes immortalized by HPV16 are sensitive
to tumour necrosis factor alpha treatment, whereas HPV18-
immortalized cells are resistant to this inhibitory cytokine
[24]. This is in part owing to different cellular
gene expression changes induced by HPV16 and HPV18,
which may contribute to the differences in the natural history
of cervical pathogenesis between these two viruses [25,26].
However, little is known about how HPV infection in the
tonsil manipulates the immune response, or whether there
are differences between HPV types at this anatomical site.
Chromosomal integration of HPV genomes is a common
feature of cervical cancers and at this body site is linked to a
poorer clinical outcome. Integration of the viral DNA most
often disrupts the E1 and E2 genes and deregulates virus
gene transcription, leading to maintained and often high
expression of the HPV oncoproteins E6 and E7 in the
tumours. However, in HPV-OPSCC the primary form of
HPV DNA is non-integrated episomes and viral DNA inte-
grants are less frequent than some earlier studies indicated;
most likely owing to a combination of the use of different
methodologies to detect episomes and/or integrants, and
ambiguities in data interpretation [27–29]. As in cervicalcancer, HPV DNA integration and a loss of expression of
the viral regulator E2 is linked to worse clinical outcomes
in OPSCC [7,30]. More recent genome-wide analyses have
led to some intriguing findings in relation to the structure
of HPV DNA in HPV-positive tumours. Work from the Gil-
lison laboratory [31] indicated that HPV16 DNA integration
was linked to insertional mutagenesis in head and neck
cancer, and cervical cancer cell lines. The viral integrants
were flanked by a myriad of genomic structural variations
and such amplifications and rearrangements were present
in HPV-positive head and neck tumours. They proposed
that these structural alterations occurred through viral
origin-directed replication of HPV16 integrants and through
a process of recombination and looping formed structural
rearrangements and viral-host sequence concatemers. A
third form of HPV DNA has been proposed by Morgan
and colleagues to be present in OPSCC—a circular, extra-
chromosomal HPV-human DNA hybrid in which the HPV
genome is a multimer (dimer or greater), but some of the
copies carry viral DNA deletions and human DNA
sequences [32]. The structure of these HPV-human DNA
hybrids suggests that during the natural history of the infec-
tion, the viral DNA was integrated into the host DNA and
through an unknown mechanism was subsequently excised
and able to replicate, most likely in an E1-E2 dependent
manner, as an HPV-human chimeric episome [29]. A
human-HPV16 chimera has been reportedly found in a cer-
vical cancer so perhaps these structures might not be unique
to the head and neck [33]. It is interesting that these host–
virus chimeric episomes were proposed in the Gillison
study [30] as a transient intermediate, replicated by rolling
circle amplification, that eventually form integrated conca-
temers with identical virus–host and virus–virus
breakpoints.
Recent analysis of the mutational landscape of
HPV-positive (predominantly OPSCC) in comparison to
HPV-negative (predominantly oral cavity) squamous cell
carcinomas provides evidence that the mutation burden in
HPV-positive tumours is indicative of apoliprotein B
mRNA editing enzyme, catalytic polypeptide-like
(APOBEC) cytidine deaminase editing [34]. Interestingly,
the mutational burden with HPV-positive tumours was
similar regardless of smoking status, suggesting that the
APOBEC-mediated innate anti-viral responses are the main
driver of genetic mutations in these tumours, although it
has been clearly demonstrated that tobacco use reduces
treatment success [15], which could reflect an attenuated
immune infiltrate induced by tobacco exposure. Further-
more, the mutational burden in HPV-positive tumours was
significantly distinct from HPV-negative tumours which dis-
played a more broad mutational signature distribution that
is reflective of heavy tobacco and alcohol use. The
APOBEC-specific mutational signature of HPV-OPSCC has
also been identified in HPV-driven cervical cancers [35]
and several of the frequently mutated genes appear to be
consistently identified at both body sites including
PIK3CA, EP300, PTEN, FBXW7 and TGFBR2. However,
several other genes found to be commonly mutated in
HPV-OPSCC, including ZNF750, FGFR3, CASZ1, CYLD
and RIPK4 have not been identified in cervical cancer [34],
indicating that the biological behaviour of HPV and natural
history of HPV-driven carcinogenesis is different at distinct
anatomical sites.
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3(a) Does the target cell for human papillomavirus
infection reside in the tonsil crypt?
The mucosa of the tongue base and tonsils (palatine and
lingual) is invaginated and forms crypts lined with reticu-
lated epithelium (figure 1). It is within these crypts that
HPV-positive tumours consistently arise, in contrast to
HPV-negative lesions that emerge mainly from the epi-
thelium lining the tonsil surface [3,36]. Unlike the stratified,
non-keratinizing epithelium of the surface of the tonsil,
which is polarized and undergoes morphological maturation,
the epithelium of the crypt is devoid of a continuous basal
lamina between the epithelium and the underlying lymphoid
stroma, and undergoes incomplete differentiation [37,38]. The
crypt keratinocytes have long slender processes that form a
desmosome-mediated network with intercellular spaces
filled with the lymphoid cells (figure 1). The crypts are also
characterized by an abundant network of intraepithelial
blood vessels [39]. The specificity of HPV tumours for such
an immunologically alert anatomical site is intriguing [40].
The disrupted nature of this lymphoepithelium may enable
the virus to readily gain access to the exposed basal keratino-
cytes and as an immune privileged site (high levels of the
lymphocyte inhibitor PD-L1 are found in the tonsil crypts,
but not in the tonsil surface epithelium [41]), the virus may
evade immune detection and clearance to establish a persist-
ent infection. However, immune presentation must occur as
HPV16 E6 seroconversion arises at least 10 years before diag-
nosis of OPSCC [42]. Also, the favourable clinical outcome of
these virus-positive tumours has been linked to a strong host
immune response with high frequency of infiltrating TIL and
inflammatory responses observed, although in some patients
a trigger of the PD-1:PD-L1 checkpoint may act to limit the
capacity of the TIL to eliminate the tumour [20,41].
Analysis of non-malignant tonsil tissue for indications of
HPV infection suggest that HPV infection at this site is rare,
even when the reticulated epithelia was sampled [43]. This
rather puzzling finding could also mean that HPV infection
is of a focal nature and limited to a small number of cells
in the crypt and hence difficult to detect. Since the HPV life
cycle is dependent on epithelial maturation for completion;
the nature of the reticulated squamous epithelia of the
crypt may not be permissive for HPV replication. Thus, if
HPV infection at this site most commonly leads to an
abortive infection with deregulation of early viral gene
expression, these cells might be at high risk of immortalization
and malignant transformation.
Mucosal squamous epithelia at different anatomical sites
that are susceptible to HPV infection are at different risks of
cancer development. The uterine cervix has a nearly 100%
association with HR HPV whereas at other sites including
anus, vagina/vulva and oropharynx, only a subset of the
tumours are HPV-associated. This differential risk between
mucosa sites could be explained by the nature of the target
cell for HPV infection, which influences disease outcome. In
the cervix, a small and discrete population of non-stratified
cuboidal cells of embryonic origin in the metaplastic trans-
formation zone at the squamocolumnar junction (SCJ) are
highly susceptible to HPV infection and from which the
majority of neoplasms arise [44]. The SCJ cells have a specific
embryonic expression profile and this expression profile is
also expressed in cervical neoplasms [45]. These cells may
provide an environment that is inhibitory/abortive to thenormal replication cycle of the virus leading to deregulated
HPV oncoprotein expression, as well as being a site of altered
adaptive immunity to enable viral persistence [46]. While a
similarly unique population of cells are found at the SCJ
between the oesophagus and gastric epithelia (and could be
cell origin of Barrett’s oesophagus), a similar cellular
makeup of the tonsil has not been identified. However, one
of the SCJ biomarkers—cytokeratin 7 (CK7)—is expressed
in the tonsil crypt, but less so in the surface squamous epithe-
lia. Notably, CK7 expression was significantly associated
with cancers of the tonsil site and that were HPV positive
[47]. Thus CK7 positive tonsil cells may represent cells
vulnerable to HPV16 infection and transformation. Intrigu-
ingly, CK7 and its binding partner cytokeratin 19 (CK19)
have been shown to be potential regulators of HPV16 E7
protein levels; CK7 binds E7 transcripts to protect them
from degradation and CK19 alleviates a translational block
imposed by CK7 [48,49]. It is worthy to note that in the
anal SCJ while multi-layers of CK7-positive cells make up
the metaplastic transition zone, only a small proportion of
HPV-positive anal neoplasms express CK7, suggesting that
CK7 positive anal cells are less susceptible to HPV infection
and/or have a reduced risk of neoplastic conversion [50].
Cervical cancer pathogenesis is characterized by a well-
defined premalignant phase of low-grade to high-grade
intraepithelial neoplasias (CIN1 to 3) that develop over
many years, but dysplastic lesions have rarely been reported
in the oropharynx. This, combined with lack of detection of
HPV productive infections at this anatomical site, the domi-
nance of HPV16-positivity and the difference in integration
rates between the two sites suggests that the natural history
of HPV-driven disease in the oropharynx is very different
to the cervix, but as yet unexplained [51].2. Modelling human papillomavirus
pathogenesis in the tonsil
One approach that has proved very successful in understand-
ing the interaction between HR HPV types and cervical
keratinocytes has been by the analysis of cells isolated from
low-grade cervical neoplasias. The most highly researched
are HPV16-positive W12 cells [52] and the HPV31-positive
CIN612 cell line [53]. Both harbour the viral genome as extra-
chromosomal episomes and upon organotypic raft culture
form reconstituted epithelia resembling the low-grade cervi-
cal lesion from which they were derived. Notably, the cell
lines show neoplastic progression upon extended culture;
the viral DNA integrates and in organotypic growth they
form a higher grade dysplastic epithelium [54–56]. While
these cell lines have been invaluable in understanding cervi-
cal pathogenesis, as yet no such premalignant cell lines have
been isolated from the oropharynx. Therefore, in this section,
we discuss how HPV infection and disease progression can
be modelled in the tonsil.
(a) Transgenic mice
Transgenic mouse models engineered to express the HPV16
oncoproteins E6 and E7 in squamous epithelia and treated
with chemical carcinogens have been very informative of
the role of the viral oncoproteins to the development of
skin, cervical, and head and neck (tongue and oesophagus)
HPV16 virus (from a
productive oral or genital infection?) tonsil
surface
tonsil
crypt
mouth
tonsil
crypt
stratified reticulated
epithelium
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Figure 1. The tonsil epithelium. A schematic of the tonsil highlighting the difference in the epithelia lining the tonsil crypt surface (stratified squamous non-
keratinized) and the crypt (stratified reticulated). The boxed region depicts the keratinocytes typical of the crypt reticulated epithelia, with long slender processes
interconnected with neighbouring cells through desmosome junctions. The intercellular spaces are filled by infiltrating lymphocytes. See text for details.
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4carcinogenesis [57–60]. These studies have shown that the
nature of the contribution of the E6 and E7 proteins to car-
cinogenesis is not equal between the different anatomical
sites, highlighting the importance of understanding E6 and
E7 biology at the correct physiological site. However, because
mice lack a tonsil equivalent, a similar approach to dissect E6
and E7 function in this lymphoid organ is not possible.
(b) Tonsil tissue explants: ex vivo
One approach that as yet has not been exploited for investi-
gating HPV-tonsil interactions is the use of tonsil explants.
Fresh human tonsils dissected into small blocks can be cul-
tured on collagen rafts at the liquid–air interface [61].
Tonsil explants have been used to study infection by viruses
including human immunodeficiency virus 1 and Epstein-Barr
virus [62]. Although these explants have a limited lifespan
and can have extensive inter- and intra-experimental vari-
ation, one advantage of the tonsil explants is that the
ex-vivo model maintains tissue cytoarchitecture, including
the major lymphocyte subtypes and follicular dendritic net-
work, and would enable HPV infection to be interrogated
in the presence of a physiological immunological landscape.
(c) Tonsil epithelium equivalents
Another approach and one that has been used extensively in
the papillomavirus field is the generation of ‘HPV infected’epithelium equivalents from primary keratinocytes grown
in three-dimensional (3D) organotypic raft culture. Keratino-
cytes harbouring the viral genomes are seeded onto a dermal
equivalent formed from rat tail type 1 collagen embedded
with fibroblasts (mouse 3T3-J2 fibroblasts are routinely used
in the HPV replication model). After a short period to
allow expansion of the keratinocytes into a confluent mono-
layer on the collagen plugs, they are lifted onto a solid
support and cultured at the air-liquid interface for a period
of about two weeks—the time it takes for a basal keratinocyte
to fully differentiate. This involves feeding the rafts from
underneath with serum-containing medium that is free of
epidermal growth factor, providing nutrients and allowing
cytokines and growth factors produced from the fibroblasts
to be delivered to the keratinocytes. The ‘raft’ system enables
analysis of the spatial and temporal organization of the virus
life cycle—from early events to viral progeny assembly
(figure 2a).
Establishment of HPV genome-containing keratinocytes
has largely relied upon transfection of HR HPV genomes
along with a drug selectable marker into primary keratino-
cytes, followed by a brief period of drug selection to
remove non-transfected cells [64]. The lifespan of the primary
keratinocytes is extended by the actions of the E6 and E7 pro-
teins, leading to immortalization of the cells and thus
establishment of cell lines harbouring the viral episomes—a
process that takes several months of cell culture. However,
virion
(a)
s s
*
i
i
b b
super-
ficial
inter-
mediate
basal
collagen
+fibroblasts
medium
viral
episome
(b) (d) (e)
(c)
Figure 2. Epithelial equivalents. (a) Cartoon of growth of tonsil keratinocytes harbouring HR HPV episomes in organotypic raft culture. Stratification for two weeks at the
liquid–air interface supports the complete productive HPV life cycle. (b) Haematoxylin and eosin stained section of primary tonsil keratinocytes and (c) foreskin ker-
atinocytes. Note the formation of the keratinized corneum (*) in foreskin keratinocyte rafts that is absent from the rafts formed from primary tonsil keratinocytes.
(d ) Haematoxylin and eosin stained section of primary tonsil keratinocytes harbouring HPV16 episomes (b, basal, i, intermediate and s, superficial layers) and (e) immu-
nostained for markers of the productive HPV life cycle: E4 protein (green) and the major capsid protein L1 (red). Nuclei are shown in blue. Scale bar, 20 mm. Dotted lines
indicate the boundary between fibroblast-embedded collagen matrix and basal keratinocytes. Details of the methods involved in preparing the primary keratinocytes,
transfection of HPV genomes, growth in organotypic raft culture and immunostaining of formalin-fixed, paraffin-embedded sections are given in [63].
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5dependence on cellular immortalization prohibits investi-
gation of immediate early events of initial viral genome
amplification and the subsequent transition to maintenance
replication, analysis of E6 and E7 immortalization defective
genomes and characterisation of virus-cell interactions that
precede immortalization. Modification of this model by
using a Cre-loxP recombination system to recombine HPV
episomes in primary cells—the loxP sites are positioned in
the upstream regulatory region downstream of the late
polyAþ site but in a region devoid of known binding fac-
tors—enables analysis of early events in the HPV life cycle
[65–67]. More recently, primary keratinocytes were success-
fully infected with HPV16 pseudovirions which had first
been conditioned on an extracellular matrix laid down by
keratinocytes expressing the transient receptor laminin 332,
and the infected primary keratinocytes supported the
complete life cycle upon 3D culture [68].
Several groups including our own, are using primary
tonsil keratinocytes to investigate HPV biology at this site
(figure 2). Because of the very high prevalence of HPV16 in
tonsil malignancies, the tonsil models have understandably
focussed on HPV16. However, there is some sense in estab-
lishing tonsil models of the HR HPV types (e.g. HPV18)
that are far less prevalent, because comparative analyses in
isogenic cells may uncover clues as to reasons for the domi-
nance of HPV16.(i) Crypt versus surface squamous tonsil keratinocytes
One important question is why the tonsil crypt is more sus-
ceptible to HPV transformation than the surface squamous
epithelium. Avery interesting study isolated tonsil progenitor
cells; cells expressing high levels of cell surface antigens CD44
and nerve growth factor receptor (NGFR) from the crypt and
the surface epithelium [69]. In surface epithelium of the
tonsil, CD44þ/NGFRþ cells are in the basal and parabasal
cell layers, but in the crypt they are found in a more
random distribution, indicating the disrupted nature of the
crypt (figure 1). The progenitor cells from both sites were
molecularly similar (enriched for pathways associated with
mobility and migration), but those from the crypt were
more primitive than those of the surface based on their
greater proliferative potential. While the lifespan of these
cells from both sites was extended to similar extents uponco-expression of the HPV16 E6 and E7 oncoproteins, differen-
tiation of the E6/E7 expressing crypt cells following 3D
stratification was more markedly disrupted compared to
the oncoprotein-expressing surface epithelial derived pro-
genitors. Whether the progenitor cells are the natural target
cell of the virus is not known but the more primitive nature
of those from the crypt may render them less permissive to
support the HPV16 life cycle and hence more susceptible to
virus-driven transformation. Perhaps introducing whole
HPV16 genomes into these cells to determine if they can
support the infectious cycle would be one route to take.
(ii) Can HPV16 infect and replicate in tonsil keratinocytes?
HPV16 does replicate in ‘unsorted’ primary tonsil keratino-
cytes following transfection of complete viral genomes or
infection with HPV16 pseudovirions [68,70,71]. Upon stratifi-
cation, the HPV16 positive cells support the production of
infectious progeny, although the conformation of the
mature virions produced in the tonsil rafts differ to those
assembled in keratinizing foreskin keratinocyte rafts [71].
The tonsil-derived virions were neutralized effectively with
anti-L1 antibodies, but neutralization was less efficient with
anti-L2 antibodies. If indeed there are structural differences
between HPV virions produced at different body sites, this
could impact on the efficacy of any future use of neutralizing
L2-based prophylactic vaccines [72].
(iii) Do tonsil keratinocytes support replication of the less
prevalent high-risk human papillomavirus types in
tonsil malignancies?
The rarity of other HR HPV types in oropharyngeal tissues
might be because these types are unable to infect these tissues
or they differ in replication potential. However, HPV18 is
very effective in extending the lifespan of tonsil keratinocytes
and the cells support HPV18 productive events upon 3D
culture ([73] (figures 3 and 4)).
(iv) Are the primary tonsil keratinocyte-based models
physiological?
When grown in organotypic raft culture, keratinocytes
from squamous epithelia of different body sites exhibit an
intrinsic potential for tissue-specific differentiation. Thus,
CK8 HPV E4
HTK
HTK-HPV18
HFK-HPV18
HTK-HPV16
HTK-HPV16
HTK-HPV18
HFK-HPV18
HTK
CK7(a) (b) HPV E4 merge
Figure 3. Cytokeratin expression in HPV-positive 3D rafts. Sections stained for (a) CK8 (Sigma-Aldrich, M20) and HPV E4, (b) CK7 (Dako Products, M701829-2) and
HPV E4. Nuclei counterstained (blue). HTK, human tonsil keratinocytes; HFK, human foreskin keratinocytes. Scale bar, 20 mm. Dotted lines or arrowheads indicate the
boundary between fibroblast-embedded collagen matrix and basal keratinocytes.
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6keratinocytes isolated from neonate foreskin tissue form a
cornified structure with a strong keratinized corneum,
whereas tonsil keratinocytes recapitulate the structure of
non-keratinizing epithelium (figure 2b,c). However, tonsil
surface and crypt epithelia undergo alternative differen-
tiation programmes and in particular, there are marked
differences in their keratin profiles [74]. Cytokeratin 8
(CK8), normally partnered with CK18 is weakly expressed
in keratinocytes of the surface tonsil epithelium (and in
basal keratinocytes), but is strongly expressed in the reticu-
lated crypt, particularly in the cells of the upper layers [74].
Another cytokeratin that distinguishes crypt from surface
epithelia is the transitional/junctional epithelia marker
CK7. In the surface epithelium, CK7 expression is low and
patchy, whereas in the crypt it is strongly expressed [47].
So, do the tonsil epithelium equivalents show CK8 and
CK7 expression patterns of the surface or the crypt, and
does HPV replication affect the expression profiles of these
cytokeratins? Our HR HPV tonsil keratinocytes models are
beginning to answer these questions. Immunostained orga-
notypic rafts of primary human tonsil keratinocytes using
anti-CK8 antibodies showed patchy CK8 staining; it was lar-
gely absent from areas of full stratification, but in areas that
were not full thickness, some basal/parabasal cells were posi-
tive for this cytokeratin (figure 3a). However, intense CK8
expression occurred in superficial cells of isogenic HPV16
and HPV18 tonsil epithelium equivalents, with low-level
staining in basal keratinocytes (figure 3a). This was specific
to the site of origin of the keratinocytes because very low
CK8 staining occurred in rafts of foreskin keratinocytes har-
bouring the HR HPV episomes (figure 3a). In the tonsil
keratinocyte rafts, CK7 was restricted to the occasional super-
ficial cell, but in HPV16 and HPV18 genome-containing
isogenic lines, the levels of this cytokeratin were markedly
increased in cells of the upper intermediate and superficiallayers corresponding to the productive phase of the HPV
life cycle (figure 3b). A similar effect on CK7 expression did
not occur in HPV18-positive foreskin keratinocyte equiva-
lents (figure 3b). These findings provide evidence that HR
HPV alters the expression pattern of tonsil crypt-specific
differentiation markers, a phenomenon that appears to be
unique to this anatomical site. HPV is known to delay differ-
entiation in the cervix to support virus replication, but in the
tonsil perhaps the virus is able to reprogramme the keratino-
cyte to express the differentiation characteristics of the tonsil
crypt. Since CK7 has been implicated in a translational mech-
anism of HPV mRNAs [49], this might be a viral mechanism
specific to the tonsil keratinocyte.
(v) Understanding neoplastic progression of human
papillomavirus driven tonsil cancer using the human
papillomavirus-tonsil models
Patients with HPV-positive oropharyngeal cancer often pre-
sent with more advanced disease compared to those with
HPV-negative OPSCC, but they have a better prognosis and
overall survival, although recurrence is still a concern
[15,75]. So while HPV positivity is a prognostic indicator,
patient survival may be further stratified based on whether
the viral genome is integrated or not in the tumour, since
clinical outcome has been shown to be worse in those
patients with integrated HPV16 and/or disruption of the
HPV E2 gene [7,16,30]. Identifying prognostic markers
among these different populations of HPV-positive disease
will be important if de-escalation treatment regimens are to
be implemented successfully.
HPV DNA integration is far less frequent in HPV OPSCC
than in the cervix; but in addition to integrated and uninte-
grated forms of the viral DNA, a third form of a viral
DNA-human hybrid has been proposed [29]. Whether these
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Figure 4. Tonsil equivalents to model HPV tonsil pathogenesis. (a) The primary tonsil keratinocytes harbouring HR HPV genomes are strong models to understand
HPV biology at this anatomical site and the virus and host changes linked to early stages of disease progression. Also, they might be a platform to test the ‘driver’
capability of host gene mutations identified in HPV-driven tonsil cancers. Refer to text for details. (b) Southern blot of tonsil-HPV cells in extended two-dimensional
cell culture shows episome loss and episome persistence; experimental details given in [63].
royalsocietypublishing.org/journal/rstb
Phil.Trans.R.Soc.B
374:20180289
7viral-human hybrids truly exist and whether they are relevant
for HPV-OPSCC pathogenesis is unclear, and as yet they
have not been reported in tonsil keratinocytes immortalized
by HPV16 genomes. However, HPV16 genomes do become
integrated into host DNA in primary tonsil cells and the
virus-cell E6-E7 mRNAs expressed are indistinguishable
from those found in HPV16-positive head and neck tumours
(figure 4), suggesting the same selective pressures occur in the
tonsil equivalents as in clinical infections and thus, they rep-
resent good models in which to study virus-cell interactions
in the progression of HPV-driven tonsil neoplasia [76].
Intriguingly, in our models of HPV replication in primary
tonsil keratinocytes, in the three donors investigated to date,
HPV18 is maintained as an episome for between 40 and 70
population doublings after which there is a marked decrease
in episomal forms of the viral genome as determined by
Southern blotting. Whereas in the same three donors,
HPV16 DNA either integrated very early upon establishment
of the cell lines (in one donor), and in the two other donors
remained episomal in extended cell culture (greater than 90
population doublings to date). While the donor sample size
is too small to conclude that HPV16 is less likely to integrate
than HPV18 in primary tonsil keratinocytes, these models are
useful to investigate differences in HPV16 and HPV18
biology and virus–host interactions in isogenic tonsilkeratinocyte backgrounds grown in short and long-term cell
culture under non-stress conditions (figure 4).3. Future directions
It is a puzzle that despite the recognition of an association
with HR HPV and OPSCC, infection at these sites in non-
malignant tissue has not been conclusively found. Primary
keratinocytes isolated from tonsil tissue are not refractory to
HPV16 infection and are able to support the production of
infectious progeny, but are the primary tonsil keratinocytes
truly representative of the target cell for the virus? If stem
cells in the crypt are the natural target and oral HPV infec-
tions may represent a source of virus to infect the tonsil,
then these cells might be less permissive for HPV replication,
leading to deregulated expression of E6 and E7. Since in the
anogenital tract, the phenotype of the HR-HPV target cell is
a determinant of carcinogenic risk, the molecular definition
of the target cell of these viruses in the tonsil is needed [50].
The reason for the prevalence of HPV16 in HPV-OPSCC is
also unclear; but primary tonsil keratinocytes support the
infectious cycle ofHPV18, that is rarely found in tonsil cancers,
so simply that this HPV type is less able to infect or replicate in
the tonsil cells seems anunlikelyexplanation ofwhywe see less
royalsocietypublishing.org/journal/rstb
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8HPV18-positive tonsil cancers. Perhaps the nature of the inter-
action between these viruses and the immune system in this
lymphoepithelial tissue is different between the various HPV
types, and this contributes to the different outcomes of infec-
tion. Further studies to understand the effects of HPV
infection and replication in tonsil keratinocytes upon innate
signalling and other arms of the immune system are needed.
With regards to this topic, RNA-Seq of gingivial keratinocytes
immortalised with the telomerase enzyme hTERT and HPV16
genomes showed downregulation of the interferon-regulated
innate signalling complex, interferon-stimulated gene factor 3
(ISGF3) and a number of the gene targets of this complex
[70]. Although, gingivial tissue is not a common site for the
development of HPV16 cancers, there was a strong correlation
between the downregulation of the ISGF3 targets between
these HPV16 immortalized cells and in HPV-positive versus
HPV-negative head and neck cancers [70]. Levels of these tar-
gets were also low in tonsil keratinocytes harbouring HPV16
episomes, suggesting that interference of this pathway is key
in HPV infections in the head and neck.
Investigation of the biology of the HPV life cycle in pri-
mary tonsils is one level of understanding of the virus–host
interaction. However, since the tonsil is a lymphoidal tissue
with significant infiltration of lymphoidal cells into the
tonsil crypt, future studies might advance these models by
co-culturing keratinocytes with immune components in
two-dimensional and 3D culture systems.
While cell lines have been established from cervical neo-
plasias and have been of huge importance in understanding
the natural history of cervical HPV pathogenesis, equivalents
from the oropharynx have not been established. This might
be because at this anatomical site the natural history of
HPV infection is very different to the cervix as either a
lengthy premalignant stage does not occur [51], or the dys-
plastic changes induced by replication of these viruses at
this body site are very mild, as suggested for HPV18 replica-
tion in the cervix [77]. Nevertheless, during the culture of the
HPV16-immortalized tonsil keratinocyte models, the viral
DNA does integrate into host DNA and at chromosomal
sites also found in HPV16-positive tumours, so they do
model virus–host events that occur in vivo [76]. Our isogenic
tonsil keratinocyte lines harbouring HPV16 or HPV18 show
differential persistence of the viral episomes upon extended
cell culture and, since the majority of HPV-driven cancers
in the oropharynx retain episomes, they provide a useful
model to investigate virus and cellular events associated
with early stages of HPV integrant- and episome-driven
tonsil pathogenesis (figure 4). Important outcomes might
also include novel viral and/or cellular targets that could
be developed into diagnostic and prognostic markers.
Performingglobal gene expression analysis on organotypic
raft cultures of primary cervical keratinocytes harbouring
HPV16 episomes revealed a number of host genes modulated
by the virus (genes associated with cell cycle progression and
DNA metabolism were upregulated whereas those genes
involved in skin development, immune response and celldeath were downregulated) that had not been observed in
HPV16-positive foreskin based models [78]. The biology of
the tonsil epithelium is very different to the cervix and global
gene analysis on the 3D HPV16 tonsil epithelial equivalents
are necessary to allowa better understanding the virus’s repro-
gramming of the host at this body site. Because HPV regulates
miRNA expression during the virus life cycle and a specific
miRNAprofile is associatedwithHPV-positive tonsil tumours
compared to virus negative malignancies, then characteriz-
ation of the virus’ effect upon the miRNA transcriptome
should also be investigated using the models [79].
Neither should studies be limited only to HPV16, but
includemodelsharbouringHRHPVtypes found less frequently
inHPV-OPSCCwhichmight aid identification of themolecular
reasons for the different pathogenicity in tonsil tissue.
It is commonly assumed that papillomaviruses evolve
slowly, but next-generation sequencing of HPV DNA isolated
from lesions is challenging this assumption and in fact inter-
host HPV genotype variability might be high, although con-
servation of E7 has been demonstrated in the cervix
[33,80,81]. There is also a degree of intra-host variability of
HPV16 genotypes across anatomical sub-sites, suggesting
that not all HPV16 infection sites are equal when it comes
to viral diversity. But what factors could be driving HPV
evolution at different infection sites? A large proportion of
these mutations are driven by the anti-viral activity of
APOBEC3. Other innate and adaptive immune pressures
may also be important and differences between the cervix
and oropharynx may, therefore, drive different levels of
HPV genotype diversity. Certainly, this is an area of ongoing
debate and more information about intra-host variability of
the HPV16 genotype is required in HPV-OPSCC; the biology
of any HPV16 variants unique to OPSCC could be tested in
the primary tonsil keratinocyte models.
In summary, it is becoming recognized that virus-driven
oropharyngeal disease is different to cervical pathogenesis:
thus the refinement and enhancement of tonsil keratinocyte-
based models will contribute to a greater understanding of
HPV disease at this anatomical site.
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